Abstract: The present invention identifies substances having the property of binding to cyclin dependent kinase (cdk) comprising: (i) a peptide including amino acid residues 84 to 103 of full length p16 protein, or an active portion or derivative thereof; or (ii) a functional mimetic of the fragment. active portion or derivative; the substance excludes full length p16. p15. p18 and p19 proteins. These substances are useful in tumour suppression by inhibiting the phosphorylation of Rb protein. Also described herein is the resolution of the amino acid motifs responsible for binding cdks, an FLD motif. corresponding to amino acid residues 90 to 92 of full length p16 protein. and an LVVL motif, corresponding to amino acid residues 94 to 97 of full length p16 protein. The substances disclosed herein can be used in the treatment of hyperproliferative disorders and to screen and design molecules having the similar properties.

Abstract: A surveillance and alarm system linked through a global communications satellite system to monitor the status of a protected mobile asset(s) or person(s). The surveillance and alarm system issues an alert in response to detection of an alarm condition. Alarm conditions include both a monitored variable, such as geographical position of the mobile asset or person with respect to an allowable range of positions, as well as triggered alarm conditions, which can be automatic such as in response to loss of main power or which can be manual such as in response to activation of a wired or wireless alarm button depressed by a person in response to a security threat. The surveillance and alarm system provides global, real-time protection for mobile equipment and personnel, as well as two-way communication between the mobile entity and a remote location.

Abstract: The present disclosure identifies substances having the property of binding to cyclin dependent kinase (cdk) comprising: (i) a peptide including amino acid residue 84 to 103 of full length p16 protein, or an active portion or derivative thereof; or (ii) a functional mimetic of the fragment, active portion or derivative; the substance excludes full length p16, p15, p18 and p19 proteins. These substances are useful in tumor suppression by inhibiting the phosphorylation of Rb protein. Also described herein is the resolution of the amino acid motifs responsible for binding cdks, an FLD motif, corresponding to amino acid residues 90 to 92 of full length p16 protein, and an LVVL motif, corresponding to amino acid residues 94 to 97 of full length p16 protein. The substances disclosed herein can be used in the treatment of hyperproliferative disorders and to screen and design molecules having the similar properties.

Abstract: Substances are disclosed which have the property of binding to PCNA, the substances comprising (i) a fragment of the p21WAF1 protein including residues 141 to 160 of the p21WAF1 amino acid sequence, or an active portion or derivative thereof; or (ii) functional mimetics of these protein fragments. In particular, the PCNA binding activity is shown to lie within the sequence motif OTSMTDFY, with the residues shown in bold being critical for PCNA binding, with those underlined being important. These substances are useful in the treatments of disorders in which PCNA is implicated, e.g. hyperproliferative disorders such as cancer and psoriasis, the substances binding to PCNA to inactivate it or functionally deplete its level. Also disclosed is the use of a yeast two hybrid screening technique for screening candidate peptides for binding to PCNA.

Abstract: A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumors is also described and claimed.

Abstract: A class of mutant forms of p53 protein, such as His273 and Lys285, which are defective in conversion from the latent to the activated state by casein kinase II, but with the ability to be activated for specific DNA binding by the action of ligands such as monoclonal antibody PAb421 and heat shock protein DnaK. Activation of these mutants, which are found at high levels in certain types of tumour, can potentially lead to selective growth arrest and induction of apoptosis in the tumor cells. p53 can be constitutively activated also by deletion of the C-terminal 30 amino acids. p53 activated in this way, or by ligand binding, can be administered for the purposes of tumour or cell growth suppression.

Abstract: A method for determining the anti-microbial activity of a putative anti-microbial agent includes combining a microbially required nucleotide phosphatase, a nucleoside phosphate and the substance to be tested, and assessing the extent of degradation of the nucleoside phosphate in the presence and absence of the substance. The method thus allows the determination of the extent of inhibition of the nucleotide phosphatase by the substance. Preferably the method determines the degree of inhibition of an RNA helicase such as DbpA, which acts selectively on prokaryotic ribosomal RNA. Suitable DbpA inhibitors as well as genetic material encoding for an active form of DbpA are used.

Abstract: A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumours is also described and claimed.

Abstract: A method of identifying a compound which interferes with the binding of MDM2 to human p53 has been determined. This method comprises forming a mixture between MDM2 and a fragment of human p53 consisting of 6 to 28 amino acids comprising TFSDLW (SEQ ID NO:2), adding a test compound to the mixture and determining the quantity of protein bound to the other before and after adding the compound. A compound which decreases the amount of binding of the two proteins to each other is a compound which interferes with the binding of MDM2 to human p53.

Abstract: Vacuum gas oil is catalytically cracked in the presence of a fluid zeolite catalyst in a riser reactor and then quenched before discharging into the disengaging section of a stripper vessel. The quench fluid is injected into the last 10 vol % of the riser reactor to prevent over cracking. In this manner, the amount of cracking which takes place in the disengaging vessel is reduced. The quench injection nozzles should be located at a point near the riser outlet but far enough from the outlet that the mixture in the riser and the quench fluid have come to temperature equilibrium by the time the mixture reaches the riser outlet. The quench fluid should be essentially inert to cracking, e.g. water or selected hydrocarbon fractions such as an intermediate cycle gas oil or heavy recycle naphtha.

Abstract: A mixture of hydrocarbons consisting of gas oil and residual oil is catalytically cracked in the presence of a fluidized zeolite catalyst. The mixture of hydrocarbons is classified by boiling range as a 550.degree.-1000.degree. F. gas oil and a 1000+.degree. F. vacuum residuum. The gas oil is selectively cracked using a freshly regenerated fluid zeolite catalyst having less than 0.1 wt % residual carbon to give a high yield of desirable liquid hydrocarbon boiling from about 60.degree.-670.degree. F. The vacuum residuum is injected into the riser reactor at a point near the riser outlet to quench the cracking reactions in the gas oil. The vacuum residuum undergoes a small amount of reaction removing undesirable materials and yielding a liquid hydrocarbon boiling up to about 1000.degree. F. The amount of vacuum residuum cracking and overall yield of liquid hydrocarbons are controlled by downstream injection of vacuum residuum into the riser.

Abstract: Anesthetic lozenges are prepared by combining an acid addition salt of 3-piperidino-p-alkoxypropiophenoneswith a molten hard candy base with either the prior or simultaneous addition of a stabilizing amount of a pharmaceutically acceptable acid such as citric acid.

Abstract: Apparatus for compressing and banding a predetermined number of generally flat, compressible articles, such as disposable diapers, includes the following. Devices are positioned at one end of the apparatus for successively receiving the articles and for positioning the articles in a longitudinally extending row. Devices are provided for moving a group of a predetermined number of the articles from the receiving and positioning devices in a generally longitudinal path of travel to the other end of the apparatus and for compressing the articles at the other end of the apparatus. Devices position banding material across the path of travel of the group of articles for allowing the banding material to position itself around the leading end and sides of the group of articles as the group is moved to the other end of the apparatus. Devices then move the banding material around the trailing end of the group of compressed articles.